The Flu Shot Hasn't Changed in 80 Years. That Might Be Over.
An FDA advisory panel just voted 9–0 to back Moderna's mRNA flu vaccine, the first of its kind. After 80 years of egg-based manufacturing, the seasonal flu shot is about to get a radical upgrade.
Every fall, the world's flu vaccine supply depends on hundreds of millions of fertilized chicken eggs. That's not a joke. It's the same basic manufacturing process we've used since 1945. The virus gets injected into eggs, grows for a while, gets harvested, and ends up in your arm. Think of it as artisanal cheesemaking, but for vaccines.
On June 18, 2026, an FDA advisory panel voted 9–0 that Moderna's mRNA flu vaccine is worth approving. Unanimous. Not a single dissent. If the FDA follows through (and it almost always does), this would be the first mRNA-based seasonal flu vaccine ever approved in the United States. That's not just a win for Moderna; it's the beginning of the end for the egg.
What the Panel Actually Said
The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed Moderna's mFlusiva, a trivalent mRNA flu vaccine designed for adults 50 and older. The panel voted on two separate questions: does the benefit outweigh the risk for adults 50–64, and does it outweigh the risk for adults 65 and up?
Both votes came back 9–0 in favor. No safety red flags. No dramatic dissents. The committee found the data "very compelling," with panelists noting that the vaccine "largely supports the safety and effectiveness" of the mRNA approach for flu.
The FDA now has until August 5, 2026 to make a final decision. Given the unanimous vote and clean safety profile, approval is widely expected.
Why 27% Matters More Than You Think
In its pivotal Phase 3 trial, mFlusiva didn't just match existing flu shots. It beat them by about 27%. That's the relative vaccine efficacy compared to a standard-dose flu shot, measured across more than 40,800 participants.
Now, 27% might not sound like a mic drop. But context matters here. Current flu vaccines are notoriously mediocre. In bad years, they're barely better than a coin flip at preventing illness. So a 27% improvement over the existing standard is like upgrading from a flip phone to a smartphone: same category, completely different experience.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The protection held up across all three flu strains the vaccine targets (two influenza A strains and one B strain), and it was consistent across age groups, including adults over 65.
The Egg Problem, Explained
To understand why this matters, you need to understand what's wrong with how we currently make flu shots.
Traditional flu vaccines require the virus to grow inside chicken eggs. But here's the catch: as the virus replicates in eggs, it mutates to adapt to its new host. By the time the vaccine is manufactured, the virus in the shot may no longer perfectly match the virus circulating in humans. It's like photocopying a photocopy; every generation loses a little fidelity.
This "egg-adapted mutation" problem is one of the biggest reasons flu vaccines underperform year after year. Cell-based and recombinant vaccines (approved in 2012 and 2013, respectively) partially solved this issue, but they still take roughly six months from strain selection to finished doses.
mRNA changes the equation entirely. Moderna's platform can go from genetic sequence to bulk vaccine in 6 to 8 weeks, compared to approximately six months for egg-based production. No eggs. No viral mutations. No supply chain that depends on poultry farming. The sequence in the vaccine matches the circulating strain exactly, because you're literally programming it with digital precision.
A $10 Billion Market Gets a New Player
The global flu vaccine market is worth roughly $9.5 to $10 billion in 2026, and it's controlled by a tight oligopoly. Sanofi, GSK, and CSL Seqirus together hold over 60% of global revenue. They've dominated for decades with egg-based, cell-based, and adjuvanted products.
Moderna is about to crash that party.
Being the first mRNA entrant into seasonal flu gives Moderna early-mover advantages, especially among healthcare providers who are already comfortable with mRNA technology from COVID vaccinations. Analysts at Evercore ISI noted that approval "could aid a return to growth" for Moderna, though they cautioned that the flu vaccine alone isn't a "fundamental thesis changer."
The real strategic play is bigger than one product. Moderna is building toward combination vaccines (flu plus COVID in a single shot). If that works, the company could offer something no egg-based manufacturer can: a single annual mRNA shot covering multiple respiratory threats.
The Fine Print
Not everything is perfectly clean. The advisory panel noted several gaps in the data that are worth watching.
First, the efficacy data comes from only one flu season. Flu strains shift dramatically year to year, so it's unclear how mFlusiva will perform when the viral landscape changes. Second, very frail elderly patients and immunocompromised individuals were underrepresented in the trials. Those are precisely the people who need protection most.
Third, there's no robust data yet on giving mFlusiva alongside other vaccines (like COVID or RSV shots) at the same visit, which is how many older adults would realistically receive it.
The FDA is addressing some of these concerns through a split approval strategy: traditional approval for adults 50–64 (where the efficacy data is strongest) and accelerated approval for adults 65 and older, contingent on a confirmatory Phase 4 trial. That means Moderna will need to keep generating evidence in seniors even after approval.
Moderna's Bigger Bet
This vote isn't just about flu. It's about proving that mRNA works outside of a pandemic.
Moderna has spent the past two years trying to convince investors (and the world) that its platform isn't a one-trick pony. COVID revenue has cratered from its pandemic peak, and the company desperately needs new products to fill the gap. A flu vaccine approval would give Moderna four commercial respiratory products in the U.S.: two COVID vaccines, an RSV vaccine (mRESVIA, already approved), and standalone flu.
Beyond respiratory, Moderna has late-stage programs in CMV (a virus that causes birth defects), cancer vaccines developed with Merck, and rare metabolic diseases. The company's stated goal is 15 launched products over five years. Flu is the proof of concept that unlocks everything else.
The Bottom Line
For 80 years, the flu shot has been a product of eggs, compromise, and modest expectations. Moderna's unanimous advisory committee win signals that the mRNA era of flu vaccination is almost here.
The FDA decision lands August 5. If approved, mFlusiva won't be available everywhere immediately (CDC recommendations and manufacturing ramp-up take time), but the symbolic importance is hard to overstate. The world's most common vaccine, made with the world's oldest technology, is about to get a 21st-century upgrade.
The eggs should be nervous.
5 min read
The Lung Cancer Drug Where Half the Patients Are Still Winning After 7 Years
Seven years into a clinical trial, more than half of metastatic lung cancer patients on Pfizer's lorlatinib still haven't progressed. Oncologists are starting to whisper the word "cure," and the data might actually justify it.
